PROBISEARCH participated in the Sci X 2019 organized by Lallemand Health Solutions held in Montreal on February 26 – 27, 2019. At the 10th edition of Scientific Exchange scientific experts in microbiome and probiotics openly discussed knowledge, research, and new clinical evidence.

Esther Jiménez, PROBISEARCH Project Director, presented the results from the randomized, double-blind, placebo-controlled, parallel group trial with 221 healthy full-term infants aged 3 to 12 months. The clinical trial conducted by Probisearch evaluated the safety and tolerability of three probiotic strains owned by Lallemand Health Solutions. Results showed that all three strains are safe and well tolerated by a healthy infant population. PROBISEARCH researchers also studied the bacterial composition in the gut of participating babies, before and after the trial period, using a mass sequencing technique, as well as their immune profile using a multiplex technology.

PROBISEARCH is a leader in probiotics research. PROBISEARCH has assembled a multidisciplinary team with expertise in the development and application of microbiological, immunological, metagenomic, transcriptomic, metabolomic and / or proteomic techniques, who have found scientific evidence on the effectiveness of their strains. Additionally, PROBISEARCH has a track record in the design and development of clinical trials in probiotics in accordance with Good Clinical Practices.